Phenotypic Drug Discovery. (Record no. 23171)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06774nam a22004813i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6424457 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724114752.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2020 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781839160790 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781788018760 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6424457 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6424457 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1230566745 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM301.25 .P446 2021 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.19 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Isherwood, Beverley. |
| 245 10 - TITLE STATEMENT | |
| Title | Phenotypic Drug Discovery. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | La Vergne : |
| Name of producer, publisher, distributor, manufacturer | Royal Society of Chemistry, The, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2020. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2021. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (272 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Issn Series |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Preface -- Foreword: Phenotypic Drug Discovery: A Personal Perspective -- PDD Comes of Age -- Managing Risk -- Added Value -- Long-term Innovation -- Closing Remarks -- References -- Contents -- Chapter 1 Phenotypic Drug Discovery: History, Evolution, Future -- 1.1 Introduction -- 1.2 History -- 1.3 Translational Knowledge Gaps -- 1.4 Formalization of Empiricism into PDD -- 1.5 The Future of PDD -- References -- Chapter 2 Development and Validation of Disease Assays for Phenotypic Screening -- 2.1 Introduction -- 2.2 Assay Design: Connecting to Clinically Relevant Biology -- 2.3 Assay Performance: Planning for Analysis -- 2.4 Triage of Phenotypic Hits -- 2.5 Mechanism Classification of Phenotypic Hits -- 2.6 Early Compound De-risking: Human Pharmacology-based Screening Funnel -- 2.7 Challenges and Opportunities: Data Management and Analysis -- 2.8 Summary and Outlook -- Acknowledgements -- References -- Chapter 3 The Development and Use of Protein and Protein-affinity Libraries for Phenotypic Screening -- 3.1 Introduction -- 3.2 Types of Protein/Protein Affinity Tools for Phenotypic Screening -- 3.3 Application of Protein-based Screening -- 3.4 A Case Study Using Secretome-based Screening - Identification of Potential Paracrine Factors that Stimulate Proliferaiton of Cardiac Cells in the Heart -- 3.5 Summary and Outlook -- Acknowledgements -- References -- Chapter 4 CRISPR/Cas-based Functional Genomic Approaches to Phenotypic Screening -- 4.1 Introduction -- 4.2 Phenotypic Screening with CRISPR/Cas -- 4.3 Functional Genomic Big Data Analytics and Artificial Intelligence -- 4.4 Summary and Outlook -- References -- Chapter 5 Contemporary Techniques for Target Deconvolution and Mode of Action Elucidation -- 5.1 Introduction -- 5.2 Affinity-based Approaches -- 5.3 Functional Genomics Approaches -- 5.4 Cellular Profiling Approaches. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 5.5 Knowledge-based and Computational Approaches -- 5.6 Discussion and Outlook -- References -- Chapter 6 Artificial Intelligence as an Enabler for Phenotypic Drug Discovery -- 6.1 Introduction -- 6.2 Data-driven Assay Development -- 6.3 Accelerating Hit Discovery with Iterative Machine Learning -- 6.4 Increasing the Throughput of Screening and Compound Triage -- 6.5 Target Deconvolution and Lead Optimization -- 6.6 Discussion and Outlook -- Abbreviations -- Acknowledgements -- References -- Chapter 7 Public-Private Partnerships to Advance Phenotypic Drug Discovery -- 7.1 Introduction -- 7.2 Collaborate to Advance Knowledge or to Compete? -- 7.3 What Works and What Doesn't in Biomedical PPP? -- 7.4 Rationale for PDD in Industry and Academia -- 7.5 Rationale of PDD PPP and Three Academic Industrial Models -- 7.6 Conclusion/Outlook -- References -- Chapter 8 Identification of a Novel Class of Small Molecules for Spinal Muscular Atrophy Through High-throughput Phenotypic Screening -- 8.1 Introduction -- 8.2 Discovery of SMN2 Splicing Modulators Through Phenotypic Screening -- 8.3 Mechanism of Action Studies -- 8.4 Summary and Implications for Other Diseases -- Acknowledgements -- References -- Chapter 9 Antibody-based Phenotypic Screening - the Discovery of Oleclumab (MEDI9447) -- 9.1 Introduction -- 9.2 Phenotypic Screening Using Combinatorial Antibody Libraries -- 9.3 In vivo Characterisation of PHEN0203 and Validation of CD73 as an Antibody-tractable Target -- 9.4 Discovery of Oleclumab -- 9.5 Testing Oleclumab in the Clinic -- 9.6 Summary and Outlook -- References -- Chapter 10 Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-ReceptorTargeting Drug for the Treatment of Schizophren -- 10.1 Introduction -- 10.2 The Development of a Novel Drug Treatment of Schizophrenia -- 10.3 Other Programs in Development -- 10.4 Conclusions. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Acknowledgements -- References -- Chapter 11 Phenotypic Screening for Drug Discovery in Tuberculosis -- 11.1 Tuberculosis Disease -- 11.2 Phenotypic Screening for Tuberculosis -- 11.3 Contribution to Clinical Successes -- 11.4 Summary and Outlook -- Acknowledgements -- References -- Chapter 12 Why an In Vivo Screening Platform Covering Broad Therapeutic Spectrum is an Ideal Tool for Drug Repositioning: Illustrated by Discovery of a Novel Class of Insulin Sensitizers -- 12.1 The Problem That Needs to Be Solved -- 12.2 The Approach That Melior Has Taken to Address the Problem -- 12.3 The MLR-1023 Story -- 12.4 Lessons Learned from 15 Years of In Vivo Phenotypic Screening -- References -- Chapter 13 Phenotypic Screen Leads to Identification of Novel Posttranscriptional Regulation Machinery for HBV -- 13.1 Introduction -- 13.2 Identification of a Small-molecule Inhibitor of HBsAg -- 13.3 Unbiased MOA Studies -- 13.4 Proposal of a Novel Mechanism and Implications of New Targets for HBV Therapeutics -- References -- Subject Index. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Phenotypic drug discovery has been highlighted in the past decade as an important strategy in the discovery of novel medical entities. This book aims to equip researchers with a thought-provoking guide to the application and development of contemporary phenotypic drug discovery for clinical success. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug development. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Augustin, Angelique. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Isherwood, Beverley |
| Title | Phenotypic Drug Discovery |
| Place, publisher, and date of publication | La Vergne : Royal Society of Chemistry, The,c2020 |
| International Standard Book Number | 9781788018760 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Issn Series |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6424457">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6424457</a> |
| Public note | Click to View |
No items available.